Jobs
-
Spexis has announced a deal with SPRIM Global Investments (SGI) for funding of up to half of Spexis’ costs related to Phase 3 development of ColiFin nebulized colistimethate sodium for the treatment of P. aeruginosa… Read more . . .
-
Tonix Pharmaceuticals has announced the initiation of the Phase 2 PREVENTION study of the company’s TNX-1900 intranasal potentiated oxytocin for the prevention of migraine headaches. Tonix licensed TNX-1900 for the treatment of migraine from Trigemina in… Read more . . .
-
Nonprofit biotech research institute Access to Advanced Health Institute (AAHI) said that it has received an award worth up to $9.9 million for a 40-month project aimed at development of liquid and dry powder versions… Read more . . .
-
Seelos Therapeutics said that it has initiated a Phase 1 study comparing PK profiles of SLS-002 intranasal racemic ketamine in Japanese and non-Asian adults. In May 2021, the company announced positive Phase 2 results for… Read more . . .
-
Pulmatrix has announced the initiation of a Phase 2b trial of its PUR1900 dry powder itraconazole in patients with allergic bronchopulmonary aspergillosis (ABPA) and asthma. In 2020, PUR1900 received fast track designation for that indication. Pulmatrix is partnered with… Read more . . .
-
Orexo announced that it has submitted an NDA for its OX124 intranasal naloxone for the reversal of opioid overdose. The company notes that FDA review is likely to take a little more than a year… Read more . . .
-
According to Liquidia, the US Patent Trial and Appeal Board (PTAB) has denied a request by United Therapeutics to revisit the board’s July 2022 determination that none of the claims in US Patent No. 10,716,793, covering Tyvaso… Read more . . .
-
Intranasal drug developer Optinose has announced the appointment of Ramy Mahmoud as CEO, succeeding Peter Miller. Mahmoud has served as Optinose’s President and Chief Operating Officer since 2010; before joining the company, he served in a number… Read more . . .
-
Aptar Pharma announced that it has launched a metal-free multidose nasal spray pump called APF Futurity for delivery of over-the-counter formulations. According to Aptar Pharma, APF Futurity is designed to be recyclable without removing the… Read more . . .
-
Device manufacturer Berry Global says that it intends to hire 500 employees over 8 years to staff its new manufacturing facility in Bangalore, India, which will produce a variety of products, including nasal and inhaled drug delivery… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland